Improving care quality by engaging patients in shared decision making

With the rapid movement towards value-based payment and delivery in health care, it is critical not to leave one of the key players behind: the patient.
Read More
Phased-in approach offers best hope for FDA’s proposed quality metrics program

In July 2015, the U.S. Food and Drug Administration (FDA) issued draft guidance for industry requiring manufacturers to provide certain manufacturing data on an annual basis. The FDA’s Center for...
Read More
Proposed quality metrics program raises operability questions

Previously in this blog series, we’ve discussed PhRMA’s main recommendation for a phased-in approach to the U.S. Food and Drug Administration’s (FDA) proposed quality metrics program, as well as...
Read More
Transparency and confidentiality in FDA’s proposed quality metrics proposal is key

In our last post on this topic, we discussed PhRMA member companies’ commitment to quality and introduced you to the U.S. Food and Drug Administration’s (FDA) proposed mandatory quality metrics...
Read More
The biopharmaceutical industry’s commitment to quality

America’s innovative biopharmaceutical companies are leaders in innovation and quality—not just in research and development, but also in manufacturing technology. PhRMA’s member companies implement...
Read More